FXR1 and cancer: The passenger deletion of FXR2 in the TP53 deletion locus renders cancer vulnerable to FXR1 inhibition, which echoes with the recently raised concept of collateral lethality in tumor suppressor gene deletion (Muller et al., 2015; Muller et al., 2012; Nijhawan et al., 2012).